Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507)
The South West Oncology Group ’s 2000 randomised-control trial investigated the addition of maintenance intravesical bacillus Calmette-Guerin (BCG) to non-muscle invasive urothelial carcinoma (NMIUC) treatment....
Source: BMC Urology - Category: Urology & Nephrology Authors: Jake Tempo, Damien Bolton and Michael O ’Callaghan Tags: Comment Source Type: research
More News: Cancer & Oncology | Carcinoma | Carcinoma in Situ | Immunotherapy | Study | Transitional Cell Carcinoma | Urology & Nephrology